Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
about
Getting TRAIL back on track for cancer therapyTrailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsHyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cellsFlavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV⁺ cellsPhase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerThree agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells.Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathwayOn the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics.Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.The role of Cullin3-mediated ubiquitination of the catalytic subunit of PP2A in TRAIL signalingModulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy.TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapyTherapeutic applications of TRAIL receptor agonists in cancer and beyond.Regulation of the Src-PP2A interaction in tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.TRAIL receptor signaling and therapeutics.Towards novel paradigms for cancer therapy.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Harnessing the cell death pathway for targeted cancer treatment.The therapeutic potential of TRAIL receptor signalling in cancer cells.TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Death receptors as targets in cancerTargeting TRAIL in the treatment of cancer: new developments.Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology.A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells.A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studiesSynergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.Phage display-derived human antibodies in clinical development and therapyTargeting apoptosis signaling in pancreatic cancerTRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.Death Receptors: New Opportunities in Cancer Therapy.Developing TRAIL/TRAIL death receptor-based cancer therapies.
P2860
Q27027460-81A8458B-30E1-47FE-A9D2-555F841B65E3Q28391040-48BA9BEB-1AE2-4902-B7C0-9D653EB8712FQ28397571-E9DDEC2F-09BD-48A4-B8FD-87F6B2B90DA4Q28817517-48503FE1-BD92-4029-B3ED-6E87BF8E60B3Q33658593-D9E4A263-D6EF-489D-A0D7-3DBB3CD04AE8Q33863928-2ACF1432-6CA1-4EB7-A924-775409616317Q34429203-3159A1CE-FB76-485C-A420-30787B7B440EQ34433792-74748110-CF93-45FF-A3E2-4C2E69F168DAQ34980866-22D60C08-4512-4915-9A68-A0B759D60F00Q35595688-A703A6D6-A65A-4883-84F4-2CDAF3CE84A3Q35853714-5B2FF9DE-4013-4950-8C99-DD6A4BA6B9CAQ35951059-094C5F1B-0A71-4579-82AF-70F9684AEF59Q36180733-293EA989-21CE-4EF9-8F7D-5201D401857FQ36482809-0015FA0F-A982-413C-B403-9C8F22B2C625Q37012681-D15FB708-7FD5-46C7-8F71-BFAB3C6B6A2DQ37071019-F6EB5C7C-1F77-4A9D-A885-CA3A3AE0D46FQ37114025-7E8BDBE5-9126-4754-8E25-3E1D0F2836C1Q37311413-12BF2413-F6A6-414D-9D90-3A7AEF35076BQ37621564-CCE180F6-C751-4721-A8AA-07CD879BE8FAQ37785559-B4475B0B-7A79-40D5-ACDC-B448CE8C351EQ37799251-8E83B26F-C7E4-4E47-A4FD-73E4AF71D865Q37913356-928FA4FC-A019-45CB-B0D3-2CE0397C1D9FQ37942090-125CFC19-EC02-4D54-B37A-B6340D1B6905Q37962655-B9CC9CCB-C115-43DF-8AC2-DD2D4C97C240Q37972139-6CB8FD11-8967-4EE3-B766-41ABB81603FAQ38103591-EB293C58-D24D-440A-BAA3-DAEF09A20726Q38500801-D4CD3302-F7CD-4625-A519-044243C5A2BCQ38557486-3B37014C-9D50-4277-9217-C5B20F186865Q38708598-B873F37F-4E6E-449F-A34F-9D8AA272149BQ39003096-8DD5F52F-099D-44B7-8DFB-CF13A90884E7Q39149515-5CFFF19B-5558-4B4C-9496-3F4547E14232Q39179377-6A5B02E2-0A7A-422D-955B-9C38EE790882Q39455419-DE34EE21-6A1C-4525-81C6-8374987CADFAQ39586282-6CAE99E9-7464-479A-A60A-EDE647CC93E1Q41416393-07473A9F-1B73-4FD2-89D0-0F1CE90A112EQ42040100-2204971F-C0B6-467E-A372-C53F57CEDA71Q42623198-C54B0C67-1B1E-4771-87B0-7B1D25F06BB3Q47108799-1E295ED5-C8F8-44EA-951A-1FA00CFB821DQ53701901-5CF90821-9304-4501-B5CC-869D680DF1BC
P2860
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.
@ast
Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.
@en
type
label
Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.
@ast
Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.
@en
prefLabel
Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.
@ast
Mapatumumab, a fully human ago ...... nd cisplatin: a phase I study.
@en
P2093
P1476
Mapatumumab, a fully human ago ...... and cisplatin: a phase I study
@en
P2093
Constantijne H Mom
Corina N A M Oldenhuis
Ferry A L M Eskens
Jaap Verweij
Norma Lynn Fox
Renée Miceli
Stefan Sleijfer
Walter J Loos
P304
P356
10.1158/1078-0432.CCR-09-0996
P407
P577
2009-08-18T00:00:00Z